Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build

Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions

Example Bundle: ePI document Bundle for bridion Package Leaflet for language en

Composition category:



Full name:


Authorised dose form:

Legal status of supply:

Domain:

Resource status:


Product classification:

Document Details

Generated Narrative: Bundle TEST PURPOSES ONLY - bridion


Document Subject

Generated Narrative: MedicinalProductDefinition mp36510bf45b0e72d68ab742851da42239

identifier: http://ema.europa.eu/identifier/EU/1/08/466/001

type: Medicinal Product

domain: Human use

status: active

legalStatusOfSupply: Medicinal product subject to medical prescription

name

productName: Bridion 100 mg/mL solution for injection

type: Full name

part

part: nan

type: Invented name part

part

part: nan

type: Scientific name part

part

part: nan

type: Strength part

part

part: nan

type: Pharmaceutical dose form part

Usages

-CountryJurisdictionLanguage
*EUEUen

Document Content

Generated Narrative: Composition composition-en-36510bf45b0e72d68ab742851da42239

Language: en

Profile: Composition (ePI)

identifier: http://ema.europa.eu/identifier/EU/1/08/466/001

status: Final

type: Package Leaflet

category: Raw

date: 2022-02-16 13:28:17+0000

author: Organization ACME industry

title: TEST PURPOSES ONLY - bridion

Attesters

-ModeTime
*Official2022-02-16 13:28:17+0000

B. Package Leaflet

unavailable

Package leaflet: Information for the user

What is in this leaflet

What is in this leaflet

  1. What Bridion is and what it is used for
  2. What you need to know before Bridion is given
  3. How Bridion is given
  4. Possible side effects
  5. How to store Bridion
  6. Contents of the pack and other information

1. What bridion is and what it is used for

What Bridion is Bridion contains the active substance sugammadex. Bridion is considered to be a Selective Relaxant Binding Agent since it only works with specific muscle relaxants, rocuronium bromide or vecuronium bromide. What Bridion is used for When you have some types of operations, your muscles must be completely relaxed. This makes it easier for the surgeon to do the operation. For this, the general anaesthetic you are given includes medicines to make your muscles relax. These are called muscle relaxants, and examples include rocuronium bromide and vecuronium bromide. Because these medicines also make your breathing muscles relax, you need help to breathe (artificial ventilation) during and after your operation until you can breathe on your own again. Bridion is used to speed up the recovery of your muscles after an operation to allow you to breathe on your own again earlier. It does this by combining with the rocuronium bromide or vecuronium bromide in your body. It can be used in adults whenever rocuronium bromide or vecuronium bromide is used and in children and adolescents (aged 2 to 17 years) when rocuronium bromide is used for a moderate level of relaxation.

2. What you need to know before you take bridion

You should not be given Bridion

  • if you are allergic to sugammadex or any of the other ingredients of this medicine (listed in section 6). Tell your anaesthetist if this applies to you. Warnings and precautions Talk to your anaesthetist before Bridion is given
  • if you have kidney disease or had in the past. This is important as Bridion is removed from your body by the kidneys.
  • if you have liver disease or have had it in the past.
  • if you have fluid retention (oedema).
  • if you have diseases which are known to give an increased risk of bleeding (disturbances of blood clotting) or anticoagulation medication. Children and adolescents This medicine is not recommended for infants less than 2 years of age. Other medicines and Bridion Tell your anaesthetist if you are taking, have recently taken or might take any other medicines. Bridion may affect other medicines or be affected by them. Some medicines reduce the effect of Bridion It is especially important that you tell your anaesthetist if you have recently taken:
  • toremifene (used to treat breast cancer).
  • fusidic acid (an antibiotic). Bridion can affect hormonal contraceptives
  • Bridion can make hormonal contraceptives - including the Pill , vaginal ring, implants or a hormonal IntraUterine System (IUS) - less effective because it reduces how much you get of the progestogen hormone. The amount of progestogen lost by using Bridion is about the same as missing one oral contraceptive Pill. If you are taking the Pill on the same day as Bridion is given to you, follow the instructions for a missed dose in the Pill s package leaflet. If you are using other hormonal contraceptives (for example a vaginal ring, implant or IUS) you should use an additional non-hormonal contraceptive method (such as a condom) for the next 7 days and follow the advice in the package leaflet. Effects on blood tests In general, Bridion does not have an effect on laboratory tests. However, it may affect the results of a blood test for a hormone called progesterone. Talk to your doctor if your progesterone levels need to be tested on the same day you receive Bridion. Pregnancy and breast-feeding Tell your anaesthetist if you are pregnant or might be pregnant or if you are breast-feeding. You may still be given Bridion, but you need to discuss it first. It is not known whether sugammadex can pass into breast milk. Your anaesthetist will help you decide whether to stop breast-feeding, or whether to abstain from sugammadex therapy, considering the benefit of breast-feeding to the baby and the benefit of Bridion to the mother. Driving and using machines Bridion has no known influence on your ability to drive and use machines. Bridion contains sodium This medicine contains up to 9.7 mg sodium (main component of cooking / table salt) in each mL. This is equivalent to 0.5 % of the recommended maximum daily dietary intake of sodium for an adult.

3. How to take bridion

Bridion will be given to you by your anaesthetist, or under the care of your anaesthetist. The dose Your anaesthetist will work out the dose of Bridion you need based on:

  • your weight
  • how much the muscle relaxant medicine is still affecting you. The usual dose is 2-4 mg per kg body weight for adults and for children and adolescents between 2-17 years old. A dose of 16 mg/kg can be used in adults if urgent recovery from muscle relaxation is needed. How Bridion is given Bridion will be given to you by your anaesthetist. It is given as a single injection through an intravenous line. If more Bridion is given to you than recommended As your anaesthetist will be monitoring your condition carefully, it is unlikely that you will be given too much Bridion. But even if this happens, it is unlikely to cause any problems. If you have any further questions on the use of this medicine, ask your anaesthetist or other doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. If these side effects occur while you are under anaesthesia, they will be seen and treated by your anaesthetist. Common side effects (may affect up to 1 in 10 people)

  • Cough
  • Airway difficulties that may include coughing or moving as if you are waking or taking a breath
  • Light anaesthesia - you may start to come out of deep sleep, so need more anaesthesia. This might cause you to move or cough at the end of the operation
  • Complications during your procedure such as changes in heart rate, coughing or moving
  • Decreased blood pressure due to the surgical procedure Uncommon side effects (may affect up to 1 in 100 people)
  • Shortness of breath due to muscle cramps of the airways (bronchospasm) occurred in patients with a history of lung problems
  • Allergic (drug hypersensitivity) reactions - such as a rash, red skin, swelling of your tongue and/or throat, shortness of breath, changes in blood pressure or heart rate, sometimes resulting in a serious decrease of blood pressure. Severe allergic or allergic-like reactions can be life threatening. Allergic reactions were reported more commonly in healthy, conscious volunteers
  • Return of muscle relaxation after the operation Frequency not known
  • Severe slowing of the heart and slowing of the heart up to cardiac arrest may occur when Bridion is administered Reporting of side effects If you get any side effects, talk to your anaesthetist or other doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store bridion

Storage will be handled by healthcare professionals. Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and on the label after EXP . The expiry date refers to the last day of that month. Store below 30 C. Do not freeze. Keep the vial in the outer carton in order to protect from light. After first opening and dilution, store at 2 to 8 C and use within 24 hours.

6. Contents of the pack and other information

What Bridion contains

  • The active substance is sugammadex. 1 mL solution for injection contains sugammadex sodium equivalent to 100 mg sugammadex. Each vial of 2 mL contains sugammadex sodium equivalent to 200 mg sugammadex. Each vial of 5 mL contains sugammadex sodium equivalent to 500 mg sugammadex.
  • The other ingredients are water for injections, hydrochloric acid 3.7% and/or sodium hydroxide. What Bridion looks like and contents of the pack Bridion is a clear and colourless to slightly yellow solution for injection. It comes in two different pack sizes, containing either 10 vials with 2 mL or 10 vials with 5 mL solution for injection. Not all pack sizes may be marketed. Marketing Authorisation Holder Merck Sharp & Dohme B.V. Waarderweg 2031 BN Haarlem The Netherlands Manufacturer N.V. Organon Kloosterstraat 6 5349 AB Oss The Netherlands Merck Sharp & Dohme B.V. Waarderweg 2031 BN Haarlem The Netherlands For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien MSD Belgium Tel/T l: +32(0)27766dpoc_belux@merck.com Lietuva UAB Merck Sharp & Dohme Tel.: +370 5 278 02 msd_lietuva@merck.com

.: +359 2 819 3info-msdbg@merck.com Luxembourg/Luxemburg MSD Belgium Tel/T l: +32(0)27766dpoc_belux@merck.com esk republika Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 dpoc_czechslovak@merck.com Magyarorsz g MSD Pharma Hungary Kft. Tel.: +36 1 888 5hungary_msd@merck.com Danmark MSD Danmark ApS Tlf: +45 4482 4dkmail@merck.com Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com Deutschland Gr nenthal GmbH Tel: +49 (0) 241 569 1service@grunenthal.com Nederland Merck Sharp & Dohme B.V. Tel.: 0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com Eesti Merck Sharp & Dohme O Tel: + 372 6144 msdeesti@merck.com Norge MSD (Norge) AS Tlf: +47 32 20 73 msdnorge@msd.no E MSD . . . . . : + 30 210 98 97 dpoc_greece@merck.com sterreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 dpoc_austria@merck.com Espa a Merck Sharp & Dohme de Espa a, S.A. Tel: +34 91 321 06 msd_info@merck.com Polska MSD Polska Sp. z o.o. Tel.: +48 22 549 51 msdpolska@merck.com France MSD France T l: + 33-(0)1 80 46 40 Portugal Merck Sharp & Dohme, Lda Tel: + 351 21 446 57 inform_pt@merck.com Hrvatska Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 croatia_info@merck.com Rom nia Merck Sharp & Dohme Romania S.R.L. Tel: + 40 21 529 29 msdromania@merck.com Ireland Merck Sharp and Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998medinfo_ireland@merck.com Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: + 386 1 5204msd_slovenia@merck.com sland Vistor hf. S mi: +354 535 7Slovensk republika Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282dpoc_czechslovak@merck.com talia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) medicalinformation.it@msd.com Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0) 9 804info@msd.fi

Merck Sharp & Dohme Cyprus Limited : 800 00 673 (+357 22866700) cyprus_info@merck.com Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700medicinskinfo@merck.com Latvija SIA Merck Sharp & Dohme Latvija Tel: + 371 67 364msd_lv@merck.com United Kingdom (Northern Ireland) Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998medinfoNI@msd.com This leaflet was last revised in <{MM/YYYY}><{month YYYY}>. Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.

The following information is intended for healthcare professionals only: For detailed information refer to the Summary of Product Characteristics of BRIDION.


Additional Resources Included in Document


Entry 1 - fullUrl = Composition/composition-en-36510bf45b0e72d68ab742851da42239

Resource Composition:

Generated Narrative: Composition composition-en-36510bf45b0e72d68ab742851da42239

Language: en

Profile: Composition (ePI)

identifier: http://ema.europa.eu/identifier/EU/1/08/466/001

status: Final

type: Package Leaflet

category: Raw

date: 2022-02-16 13:28:17+0000

author: Organization ACME industry

title: TEST PURPOSES ONLY - bridion

Attesters

-ModeTime
*Official2022-02-16 13:28:17+0000

Entry 2 - fullUrl = MedicinalProductDefinition/mp36510bf45b0e72d68ab742851da42239

Resource MedicinalProductDefinition:

Generated Narrative: MedicinalProductDefinition mp36510bf45b0e72d68ab742851da42239

identifier: http://ema.europa.eu/identifier/EU/1/08/466/001

type: Medicinal Product

domain: Human use

status: active

legalStatusOfSupply: Medicinal product subject to medical prescription

name

productName: Bridion 100 mg/mL solution for injection

type: Full name

part

part: nan

type: Invented name part

part

part: nan

type: Scientific name part

part

part: nan

type: Strength part

part

part: nan

type: Pharmaceutical dose form part

Usages

-CountryJurisdictionLanguage
*EUEUen